The Affiliated Changzhou Tumor Hospital of Suzhou University
Endostar is free supported by Shangdong Simcere Medgene biotech co.,Ltd. Endostar combination with Chemotherapy has been the first line treatment regimen to advanced NSCLC. Clinical data proved that Endostar was a wild spectrum and safe antiangiogenesis factor which could suppress almost 65 kinds of tumor mass in animal models and affect about 12 percent human genome. China NCCN colon or rectal cancer clinical practice guideline recommends Chemotherapy plus angiogenesis inhibitor as the first line treatment scheme. So we design FOLFOX4 plus Endostar to treat advanced colorectal cancer to research the RR and safety. We believe this treatment regimen may be a new approach to the advanced colorectal cancer patients.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with histologically or cytologically confirmed metastatic CRC
Measurable disease according to Response Criteria In Solid Tumours (RECIST)
Performance Status 0 - 2 according to ECOG (Eastern Cooperative Oncology Group) Performance Status
Age 18\~75
Life expectancy \> 3 months
Signed informed consent (IC)
Adequate haematological and biological functions
You may not be if
Pregnant or lactating women
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drugs
Neuropathy, brain, or leptomeningeal involvement
Treatment with any biologic, cytotoxic, radiation , or hormonal therapy within four weeks.
Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months or high risk/uncontrolled arrhythmia
Uncontrolled significant comorbid conditions and previous radiotherapy
Clareo Health | FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer
